FIGURE

Fig. 5

ID

ZDB-FIG-160824-16

Publication

Dang et al., 2016 - Long-term drug administration in the adult zebrafish using oral gavage for cancer preclinical studies

Other Figures

All Figure Page

Back to All Figure Page

Fig. 5

BRAF^V600E inhibitor treatment of primary zebrafish melanoma tumors. (A) On the left, a representative MCR:eGFP zebrafish with primary tumors along its dorsal side was treated with DMSO control for 2weeks via oral gavage. On the right, a representative MCR:eGFP zebrafish with primary tumors along its dorsal side was treated with 100mg/kg Vemurafenib for 2weeks via oral gavage. The fixed dotted red line represents the tumor area pre-treatment. (B) Average percent change from baseline of tumor area based on pigmentation in a cohort with n=6 in the both the DMSO- or Vemurafenib-treated arm. Two-tailed paired t-test was performed for statistical analysis. Data represented as mean�s.d. of three replicates. (C) Waterfall plots depict the range of response for the experimental cohorts, DMSO and Vemurafenib. The response was quantified by percent change of tumor area from baseline.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Dis. Model. Mech.